Literature DB >> 22145935

The prion protein unstructured N-terminal region is a broad-spectrum molecular sensor with diverse and contrasting potential functions.

Maxime Béland1, Xavier Roucou.   

Abstract

The physiological function of the prion protein (PrP(C) ) and its conversion into its infectious form (PrP(Sc) ) are central issues to understanding the pathogenesis of prion diseases. The N-terminal moiety of PrP(C) (NH(2) -PrP(C) ) is an unstructured region with the characteristic of interacting with a broad range of partners. These interactions endow PrP(C) with multifunctional and sometimes contrasting capabilities, including neuroprotection and neurotoxicity. Recently, binding of β-sheet rich conformers to NH(2) -PrP(C) demonstrated a probable neurotoxic function for PrP(C) in Alzheimer's disease. NH(2) -PrP(C) also enhances the propagation of prions in vivo and is the target of the most potent antiprion compounds. Another level of complexity is provided by endoproteolysis and release of most of NH(2) -PrP(C) into the extracellular space. Further studies will be necessary to understand how NH(2) -PrP(C) regulates the physiological function of PrP(C) and how it is involved in the corruption of its normal function in diseases.
© 2011 The Authors. Journal of Neurochemistry © 2011 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22145935     DOI: 10.1111/j.1471-4159.2011.07613.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  32 in total

1.  The P's and Q's of cellular PrP-Aβ interactions.

Authors:  David Westaway; Jack H Jhamandas
Journal:  Prion       Date:  2012-08-09       Impact factor: 3.931

2.  PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity.

Authors:  David Mengel; Wei Hong; Grant T Corbett; Wen Liu; Alexandra DeSousa; Laura Solforosi; Cheng Fang; Matthew P Frosch; John Collinge; David A Harris; Dominic M Walsh
Journal:  Brain Res       Date:  2018-12-26       Impact factor: 3.252

3.  Proteolytic processing of the prion protein in health and disease.

Authors:  Hermann C Altmeppen; Berta Puig; Frank Dohler; Dana K Thurm; Clemens Falker; Susanne Krasemann; Markus Glatzel
Journal:  Am J Neurodegener Dis       Date:  2012-05-15

4.  Thermodynamic characterization of the unfolding of the prion protein.

Authors:  Roumita Moulick; Jayant B Udgaonkar
Journal:  Biophys J       Date:  2014-01-21       Impact factor: 4.033

5.  Melanin or a Melanin-Like Substance Interacts with the N-Terminal Portion of Prion Protein and Inhibits Abnormal Prion Protein Formation in Prion-Infected Cells.

Authors:  Taichi Hamanaka; Keiko Nishizawa; Yuji Sakasegawa; Ayumi Oguma; Kenta Teruya; Hiroshi Kurahashi; Hideyuki Hara; Suehiro Sakaguchi; Katsumi Doh-Ura
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

Review 6.  Taking advantage of physiological proteolytic processing of the prion protein for a therapeutic perspective in prion and Alzheimer diseases.

Authors:  Maxime Béland; Xavier Roucou
Journal:  Prion       Date:  2014 Jan-Feb       Impact factor: 3.931

7.  Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo.

Authors:  Tomas Ondrejcak; Igor Klyubin; Grant T Corbett; Graham Fraser; Wei Hong; Alexandra J Mably; Matthew Gardener; Jayne Hammersley; Michael S Perkinton; Andrew Billinton; Dominic M Walsh; Michael J Rowan
Journal:  J Neurosci       Date:  2018-10-24       Impact factor: 6.167

8.  Domain-Specific Activation of Death-Associated Intracellular Signalling Cascades by the Cellular Prion Protein in Neuroblastoma Cells.

Authors:  Silvia Vilches; Cristina Vergara; Oriol Nicolás; Ágata Mata; José A Del Río; Rosalina Gavín
Journal:  Mol Neurobiol       Date:  2015-08-07       Impact factor: 5.590

9.  Homodimerization as a molecular switch between low and high efficiency PrP C cell surface delivery and neuroprotective activity.

Authors:  Maxime Béland; Xavier Roucou
Journal:  Prion       Date:  2013-01-28       Impact factor: 3.931

10.  Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents.

Authors:  Yervand Eduard Karapetyan; Gian Franco Sferrazza; Minghai Zhou; Gregory Ottenberg; Timothy Spicer; Peter Chase; Mohammad Fallahi; Peter Hodder; Charles Weissmann; Corinne Ida Lasmézas
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.